Lynparza With Abiraterone and Prednisone (or Prednisolone) Approved for BRCA-mutated mCRPC

The FDA approved olaparib (Lynparza, AstraZeneca) with abiraterone and prednisone (or prednisolone) for adult ...

JUNE 2, 2023

PROfound Trial: OS Improvement With Olaparib in Subset of Patients With mCRPC

In men with metastatic castration-resistant prostate cancer and mutations in genes associated with homologous ...

MARCH 3, 2021

Lynparza Approved for Use in HRR-Mutated mCRPC

The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected ...

MAY 28, 2020

FDA Grants New Pancreatic Cancer Indication for Lynparza

Lynparza can now be used for the maintenance treatment of adult patients with deleterious or suspected deleterious ...

JANUARY 7, 2020

Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial

Maintenance therapy with olaparib can reduce the risk for ovarian cancer disease progression and related death by ...

NOVEMBER 27, 2018

Lynparza Approved to Treat BRCA-Mutated Metastatic Breast Cancer

The FDA expanded the approved use of olaparib (Lynparza, AstraZeneca) to include the treatment of patients with ...

JANUARY 14, 2018

Olaparib Provides PFS Benefit in Pts With HER2-Negative Breast Cancer

Chicago—Relative to single-agent chemotherapies, olaparib delays time to both first and second progression in ...

JULY 12, 2017

Olaparib Maintenance Shows Benefit in Ovarian Cancer

Depiction of an ovarian cancer blood test. Chicago—Maintenance therapy with olaparib can improve outcomes in ...

SEPTEMBER 19, 2016